WO2020244348A1 - 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型 - Google Patents
呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型 Download PDFInfo
- Publication number
- WO2020244348A1 WO2020244348A1 PCT/CN2020/088121 CN2020088121W WO2020244348A1 WO 2020244348 A1 WO2020244348 A1 WO 2020244348A1 CN 2020088121 W CN2020088121 W CN 2020088121W WO 2020244348 A1 WO2020244348 A1 WO 2020244348A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- crystal form
- solvent
- ethanol
- Prior art date
Links
- 150000001875 compounds Chemical group 0.000 title claims abstract description 414
- 239000013078 crystal Chemical group 0.000 title claims abstract description 191
- 150000003839 salts Chemical class 0.000 title abstract description 10
- 238000001308 synthesis method Methods 0.000 title abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 54
- 238000002360 preparation method Methods 0.000 claims abstract description 46
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 330
- 238000003756 stirring Methods 0.000 claims description 168
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 135
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 132
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 124
- 239000007787 solid Substances 0.000 claims description 118
- 239000000243 solution Substances 0.000 claims description 113
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 103
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 99
- 239000012065 filter cake Substances 0.000 claims description 98
- 239000002904 solvent Substances 0.000 claims description 83
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 72
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 70
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 67
- 229910052757 nitrogen Inorganic materials 0.000 claims description 52
- 229910019142 PO4 Inorganic materials 0.000 claims description 47
- 239000010452 phosphate Substances 0.000 claims description 47
- 239000000706 filtrate Substances 0.000 claims description 41
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 41
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 39
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 37
- 239000012141 concentrate Substances 0.000 claims description 37
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 35
- 239000000463 material Substances 0.000 claims description 34
- 239000007864 aqueous solution Substances 0.000 claims description 33
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 32
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 24
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 23
- 239000000725 suspension Substances 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 21
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 21
- -1 compound sulfate salt Chemical class 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 20
- 238000002425 crystallisation Methods 0.000 claims description 19
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 16
- SXQFCVDSOLSHOQ-UWTATZPHSA-N (R)-(+)-Lactamide Chemical compound C[C@@H](O)C(N)=O SXQFCVDSOLSHOQ-UWTATZPHSA-N 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 15
- 230000008025 crystallization Effects 0.000 claims description 13
- 239000012046 mixed solvent Substances 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 9
- 239000012074 organic phase Substances 0.000 claims description 9
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 7
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical class [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 238000002604 ultrasonography Methods 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims 1
- 102000015774 TYK2 Kinase Human genes 0.000 abstract description 10
- 108010010057 TYK2 Kinase Proteins 0.000 abstract description 10
- 238000009776 industrial production Methods 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 102000002295 Janus Kinase 1 Human genes 0.000 abstract description 3
- 108010000837 Janus Kinase 1 Proteins 0.000 abstract description 3
- 229940043355 kinase inhibitor Drugs 0.000 abstract description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract description 3
- 238000009509 drug development Methods 0.000 abstract description 2
- ZFQNHUSKKDBFHY-GRYCIOLGSA-N 2-[(2R,5S)-5-[4-[(1R)-1-hydroxyethyl]-12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,10-pentaen-3-yl]oxan-2-yl]acetonitrile Chemical compound O[C@H](C)C1=NC=2C(=C3C(=NC=2)C=CO3)N1[C@H]1CC[C@@H](OC1)CC#N ZFQNHUSKKDBFHY-GRYCIOLGSA-N 0.000 abstract 1
- AQCQKDBQDZRGAH-UHFFFAOYSA-N 7-chloro-6-nitrofuro[3,2-b]pyridine Chemical compound C1(=C(Cl)C=2OC=CC=2N=C1)N(=O)=O AQCQKDBQDZRGAH-UHFFFAOYSA-N 0.000 abstract 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 abstract 1
- 238000006722 reduction reaction Methods 0.000 abstract 1
- 238000007363 ring formation reaction Methods 0.000 abstract 1
- 239000007858 starting material Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 33
- 238000012360 testing method Methods 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- 238000000113 differential scanning calorimetry Methods 0.000 description 23
- 239000002244 precipitate Substances 0.000 description 23
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- 238000010992 reflux Methods 0.000 description 18
- 238000001228 spectrum Methods 0.000 description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 238000002390 rotary evaporation Methods 0.000 description 14
- 230000008569 process Effects 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 7
- 238000001291 vacuum drying Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000005909 Kieselgur Substances 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 238000007670 refining Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 238000010009 beating Methods 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 101150069380 JAK3 gene Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229910005429 FeSSIF Inorganic materials 0.000 description 2
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 2
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 101150009057 JAK2 gene Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012296 anti-solvent Substances 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- OEZNULIHEQCKJR-UHFFFAOYSA-N ethanol;hydrobromide Chemical compound Br.CCO OEZNULIHEQCKJR-UHFFFAOYSA-N 0.000 description 2
- PEZBJHXXIFFJBI-UHFFFAOYSA-N ethanol;phosphoric acid Chemical compound CCO.OP(O)(O)=O PEZBJHXXIFFJBI-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- HGNXHCJAXKQSOQ-UHFFFAOYSA-N 12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,3,6,8,10-pentaene Chemical class N1C=NC=2C1=C1C(=NC=2)C=CO1 HGNXHCJAXKQSOQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- SYZWSSNHPZXGML-UHFFFAOYSA-N dichloromethane;oxolane Chemical compound ClCCl.C1CCOC1 SYZWSSNHPZXGML-UHFFFAOYSA-N 0.000 description 1
- BLEBFDYUDVZRFG-UHFFFAOYSA-N dichloromethane;propan-2-ol Chemical compound ClCCl.CC(C)O BLEBFDYUDVZRFG-UHFFFAOYSA-N 0.000 description 1
- FDSGHYHRLSWSLQ-UHFFFAOYSA-N dichloromethane;propan-2-one Chemical compound ClCCl.CC(C)=O FDSGHYHRLSWSLQ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to the field of drug synthesis, in particular to the compound 2-[(2R,5S)-5-[2-[(R)-1-hydroxyethyl]furo[3, as a selective Jak1/TYK2 kinase inhibitor Synthesis method of 2-b]imidazo[4,5-d]pyridin-1-yl]tetrahydropyran-2-yl]acetonitrile (hereinafter referred to as compound I).
- compound I 2-b]imidazo[4,5-d]pyridin-1-yl]tetrahydropyran-2-yl]acetonitrile
- the present invention also relates to the crystal form of Compound I, the crystal form of its salt and their preparation method.
- the present invention also relates to pharmaceutical compositions and pharmaceutical preparations containing the crystal form of Compound I and/or the crystal form of its salt, and the crystal form of Compound I and the crystal form of its salt in the treatment of diseases and diseases related to Jak1/TYK2. The use of the condition.
- Protein kinases represent a large family of proteins that play an important role in regulating various cellular processes and maintaining cell functions. These kinases include at least: non-receptor tyrosine kinases, such as the Janus kinase family (Jak1, Jak2, Jak3, and TYK2); receptor tyrosine kinases, such as platelet-derived growth factor receptor kinase (PDGFR); and serine/threon Amino kinase, such as b-RAF.
- non-receptor tyrosine kinases such as the Janus kinase family (Jak1, Jak2, Jak3, and TYK2)
- receptor tyrosine kinases such as platelet-derived growth factor receptor kinase (PDGFR)
- PDGFR platelet-derived growth factor receptor kinase
- serine/threon Amino kinase such as b-RAF.
- the Janus kinase family contains 4 known family members: Jak1, Jak2, Jak3 and Tyrosine Kinase 2 (TYK2). These cytoplasmic tyrosine kinases are associated with membrane cytokine receptors (such as the common gamma-chain receptor and glycoprotein 130 (gp130) transmembrane protein) (Murray, J. Immunol. 178(5): 2623-2629, 2007 ). Almost 40 cytokine receptors signal through the combination of these 4 Jak family members and their 7 downstream substrates: signal transduction activators of transcription (STAT) family members (Ghoreschi et al., Immunol Rev.228(l):273 -287, 2009).
- STAT signal transduction activators of transcription
- Cytokines that bind to their receptors initiate Jak activation via mutual and autophosphorylation initiate Jak activation via mutual and autophosphorylation.
- the Jak family kinases in turn phosphorylate cytokine receptor residues, creating binding sites for proteins containing sarcoma homology 2 (SH2) (such as STAT factors and other regulators), which are subsequently activated by Jak phosphorylation.
- SH2 proteins containing sarcoma homology 2
- STAT proteins containing sarcoma homology 2
- the activated STAT enters the nucleus and begins to promote the expression of survival factors, cytokines, chemokines and molecules that promote leukocyte cell trafficking (Schindler et al., J. Biol. Chem. 282(28): 20059-20063, 2007).
- Jak activation also leads to cell proliferation via phosphoinositide 3-kinase (PI3K) and protein kinase B-mediated pathways.
- PI3K phospho
- Jak3 and Jak1 are components of common ⁇ -chain cytokine receptor complexes, and blocking of either of these two inhibits inflammatory cytokines (interleukin (IL)-2,4,7,9,15). And 21) signal transduction (Ghoreschi et al., Immunol. Rev. 228(l):273-287, 2009). In contrast, other pathologically related cytokines (such as IL-6) rely only on Jak1. Therefore, Jak1 blockade inhibits the signal transduction of many pro-inflammatory cytokines (Guschin et al, EMBO J.14(7):1421-1429, 1995).
- Biological test results show that Compound I is a potent and selective Jak1 inhibitor, and shows selective inhibition of IL-6-induced STAT3 phosphorylation, but not thrombopoietin-induced STAT3 phosphorylation .
- the international patent application WO2018067422A1 does not disclose the biological activity of TYK2, and the disclosed preparation method of compound I has a high reaction temperature, high impurities, low product yield, and is not suitable for industrial production. Therefore, it is necessary to develop a preparation method of compound I with mild reaction conditions, high product yield, high purity and suitable for industrial production.
- the object of the present invention is to provide a method for preparing a compound of formula I (ie, compound I) that is suitable for industrial production with mild reaction conditions, high product yield, high purity, and the synthetic route of the method is as follows:
- the method includes the following steps:
- step 1
- the pH of the system is adjusted to 1-3, extracted with an organic solvent, the organic phase is discarded, the pH of the aqueous phase is adjusted to 9-10 with an inorganic alkali aqueous solution, filtered, and the filter cake is dried to obtain the compound of formula I.
- step 1 in step 1 above:
- volume-to-mass ratio (mL/g) of ethanol to the compound of formula IV is 5:1 to 20:1, preferably 10:1;
- the molar ratio of the compound of formula IV, the compound of formula V and DIPEA is 1:1 ⁇ 1.1:2 ⁇ 3, preferably 1:1.01:2.2;
- the volume-to-mass ratio (mL/g) of the water dropped into the system and the compound of formula IV is 10:1 to 20:1, preferably 15:1;
- the filter cake is washed with an aqueous ethanol solution.
- the volume ratio of ethanol to water (mL/mL) in the ethanol aqueous solution is 1:1 to 1:2, preferably 1:1.5 to 1:2; the volume of the ethanol aqueous solution and the compound of formula IV
- the mass ratio (mL/g) is 2:1 to 10:1, preferably 2:1 to 5:1, more preferably 2:1 to 3:1;
- the filter cake is dried in vacuum or blown air at 45-55°C, preferably 50°C.
- step 2 in step 2 above:
- the volume-to-mass ratio (mL/g) of tetrahydrofuran to the compound of formula III is 10:1 to 70:1, preferably 20:1 to 70:1;
- Palladium-carbon is 5% Pd/C, 50% wet palladium-carbon, and the mass ratio (g/g) of palladium-carbon to the compound of formula III is 0.15:1 to 0.16:1, preferably 0.15:1;
- the filter cake was washed with tetrahydrofuran, and the filtrate was combined and concentrated to obtain the formula II compound concentrate as the tetrahydrofuran solution of the formula II compound, wherein the volume mass ratio (mL/g) of the tetrahydrofuran used for washing to the formula II compound was 2:1 to 4:1, preferably 2:1 to 3:1 (the mass of the compound of formula II obtained in step 2 according to 100% yield); preferably, the tetrahydrofuran solution of the compound of formula II is replaced with ethanol to obtain the ethanol of the compound of formula II A solution in which the volume-to-mass ratio (mL/g) of ethanol to the compound of formula II is 2:1 to 5:1, preferably 2:1 to 4:1, more preferably 2:1 to 3:1 (step 2 is 100% The mass of the compound of formula II obtained after yield conversion).
- the volume mass ratio (mL/g) of the tetrahydrofuran used for washing to the formula II compound was 2:1 to 4:1, preferably 2:1 to 3:1 (the mass of the compound of formula II
- step 3 in step 3 above:
- volume-to-mass ratio (mL/g) of tetrahydrofuran to the compound of formula II concentrate is 6:1 to 12:1;
- volume-to-mass ratio (mL/g) of ethanol and the compound of formula II concentrate is 10:1 to 16:1, preferably 14:1;
- the material in the second reaction vessel is heated to 40-85°C, preferably 45-70°C, more preferably 45-50°C;
- the pH value of the system is adjusted to 1-3 with hydrochloric acid.
- the hydrochloric acid is 1M HCl or 12M HCl, preferably 12M HCl;
- the inorganic alkali aqueous solution is saturated sodium carbonate aqueous solution or saturated potassium carbonate aqueous solution, preferably saturated potassium carbonate aqueous solution;
- the organic solvent used for extraction is dichloromethane or ethyl acetate
- the filter cake is vacuum-dried or air-dried at 50-55°C.
- Another object of the present invention is to provide a crystalline form of the compound of formula I, which is referred to as crystalline form 1 of the compound of formula I herein.
- the X-ray powder diffraction pattern of the crystal form 1 of the compound of formula I of the present invention has characteristic peaks at 2theta values of 8.5° ⁇ 0.2°, 14.8° ⁇ 0.2°, and 16.1° ⁇ 0.2°.
- the X-ray powder diffraction pattern of the crystal form 1 of the compound of formula I of the present invention has a 2theta value of 8.5° ⁇ 0.2°, 14.8° ⁇ 0.2°, 16.1° ⁇ 0.2°, 17.1° ⁇ 0.2°, There are characteristic peaks at 18.8° ⁇ 0.2° and 19.6° ⁇ 0.2°.
- the X-ray powder diffraction pattern of the crystalline form 1 of the formula I compound of the present invention has a 2theta value of 8.5° ⁇ 0.2°, 14.8° ⁇ 0.2°, 16.1° ⁇ 0.2°, 17.1° ⁇ 0.2° , 18.8° ⁇ 0.2°, 19.6° ⁇ 0.2°, 23.8° ⁇ 0.2°, 25.3° ⁇ 0.2°, 26.1° ⁇ 0.2° have characteristic peaks.
- XRPD X-ray powder diffraction
- the differential scanning calorimetry (DSC) spectrum of the crystalline form 1 of the compound of formula I of the present invention is shown in FIG. 2A.
- the DSC spectrum shows that the initial melting point of the crystalline form 1 of the compound of formula I of the present invention is 160.76°C, and the broad endothermic peak at 91.85°C is a dehydrated solvent peak.
- the thermal weight loss analysis (TGA) chart of the crystal form 1 of the compound of formula I of the present invention is shown in FIG. 3.
- the TGA chart shows that the crystal form 1 of the compound of formula I of the present invention has a step weight loss of 5.353% when heated from 25°C to 133°C, which corresponds to the weight percentage of one molecule of water lost.
- the dynamic moisture adsorption (DVS) spectrum of the crystalline form 1 of the compound of formula I of the present invention is shown in FIG. 4.
- the DVS spectrum shows that the compound of formula I of the present invention has a moisture absorption weight gain of 5.2% from 0%RH to 95%RH, indicating that the sample absorbs moisture, but the water cannot be completely removed during the desorption process (2% remaining).
- the present invention provides a method for preparing crystal form 1 of the compound of formula I, which is specifically as follows:
- the compound of formula I is dissolved in a solvent, stirred at room temperature, water is added to the solution of the compound of formula I, stirred, filtered, and dried to obtain crystal form 1 of the compound of formula I.
- the solvent is selected from one or more of acetone, methanol, and water; the solvent is preferably acetone, or a mixed solvent of methanol and water, or a mixed solvent of acetone and water, wherein methanol and
- the volume ratio of methanol to water (mL/mL) in the mixed solvent of water is 30:1 to 1:1, preferably 9:1, and the volume ratio of acetone to water (mL/mL) in the mixed solvent of acetone and water is 6 :1 to 1:1, preferably 4:1.
- the volume mass ratio (mL/g) of the solvent to the compound of formula I is 20:1 to 45:1, and the volume mass of the water added to the solution of the compound of formula I and the compound of formula I
- the ratio (mL/g) is 20:1 to 90:1.
- the compound of formula I is dissolved in a solvent at 50-60°C.
- a solvent is added to the compound of formula I, and the suspension of the compound of formula I is obtained by ultrasound.
- the suspension of the compound of formula I is protected from light and stirred, centrifuged, and the solid is collected to obtain the crystal form 1 of the compound of formula I.
- the solvent is selected from one or more of tetrahydrofuran, methyl tert-butyl ether, water, acetone, isopropanol, dichloromethane, and ethanol.
- the suspension of the compound of formula I is stirred at room temperature, or at 45-55°C, preferably at 50°C.
- the suspension of the compound of formula I is protected from light and stirred for 6-10 days.
- the solvent is selected from one or more of acetone, tetrahydrofuran, and dichloromethane.
- the temperature is slowly lowered to room temperature at a rate of 6°C/h, and then cooled at -20-10°C, preferably 2-8°C, to crystallize .
- the first solvent is added to the compound of formula I, the supersaturated solution of the compound of formula I is obtained by ultrasound, filtered, the second solvent is added to the filtrate and stirred, centrifuged, and the solid is collected to obtain the crystal form 1 of the compound of formula I.
- the first solvent is selected from one or more of methanol, ethanol, tetrahydrofuran, acetone, and isopropanol
- the second solvent is selected from water, methyl tert-butyl ether, di One or more of methyl chloride.
- the volume ratio (mL/mL) of the first solvent to the second solvent is 1:5 to 1:20, preferably 1:10.
- Another object of the present invention is to provide the crystalline form of the compound salt of formula I, specifically the crystalline form of the compound of formula I hydrochloride, the crystalline form of sulfate, the crystalline form of hydrobromide, and the crystalline form of phosphate. They are called the hydrochloride crystal form A, sulfate crystal form B, hydrobromide crystal form C, and phosphate crystal form D of the compound of formula I, respectively.
- the X-ray powder diffraction pattern of the hydrochloride salt of the formula I compound of the present invention has characteristic peaks at 2theta values of 6.4° ⁇ 0.2°, 12.8° ⁇ 0.2°, 14.2° ⁇ 0.2°, and 19.0° ⁇ 0.2°.
- the X-ray powder diffraction pattern of the hydrochloride salt form A of the compound of formula I of the present invention has a 2theta value of 6.4° ⁇ 0.2°, 8.5° ⁇ 0.2°, 11.6° ⁇ 0.2°, 12.8° ⁇ There are characteristic peaks at 0.2°, 14.2° ⁇ 0.2°, 17.1° ⁇ 0.2°, and 19.0° ⁇ 0.2°.
- the X-ray powder diffraction pattern of the compound of formula I hydrochloride crystal form A of the present invention has a 2theta value of 6.4° ⁇ 0.2°, 8.5° ⁇ 0.2°, 11.6° ⁇ 0.2°, 12.8° There are characteristic peaks at ⁇ 0.2°, 14.2° ⁇ 0.2°, 17.1° ⁇ 0.2°, 19.0° ⁇ 0.2°, 19.7° ⁇ 0.2°, 21.3° ⁇ 0.2°, 24.5° ⁇ 0.2°.
- the present invention provides a method for preparing the hydrochloride crystal form A of the compound of formula I, which is specifically as follows:
- the compound of formula I is dissolved in a solvent under ultrasonic heating.
- the solvent is one or more of ethanol, acetone, acetonitrile and isopropanol.
- the concentration of the ethanol solution of hydrochloric acid is 30-60 mg/mL, preferably 50 mg/mL.
- stirring is continued at room temperature for 4-24 hours.
- the X-ray powder diffraction pattern of the sulfate salt crystal form B of the formula I compound of the present invention has characteristic peaks at 2theta values of 12.2° ⁇ 0.2°, 17.1° ⁇ 0.2°, 18.4° ⁇ 0.2°, and 20.1° ⁇ 0.2°.
- the X-ray powder diffraction pattern of the compound of formula I sulfate salt crystal form B of the present invention has a 2theta value of 12.2° ⁇ 0.2°, 17.1° ⁇ 0.2°, 18.4° ⁇ 0.2°, 19.6° ⁇ 0.2 °, 20.1° ⁇ 0.2°, 20.6° ⁇ 0.2°, 22.1° ⁇ 0.2° have characteristic peaks.
- the X-ray powder diffraction pattern of the crystalline form B of the compound of formula I of the present invention has a 2theta value of 12.2° ⁇ 0.2°, 17.1° ⁇ 0.2°, 18.4° ⁇ 0.2°, 19.6° ⁇ There are characteristic peaks at 0.2°, 20.1° ⁇ 0.2°, 20.6° ⁇ 0.2°, 22.1° ⁇ 0.2°, 23.5° ⁇ 0.2°, 26.8° ⁇ 0.2°, 29.3° ⁇ 0.2°.
- the present invention provides a preparation method of the compound of formula I sulfate salt crystal form B, which is specifically as follows:
- the compound of formula I is dissolved in a solvent under ultrasonic heating.
- the solvent is one or more of ethanol, acetone, acetonitrile and isopropanol.
- the concentration of the ethanol solution of sulfuric acid is 30-60 mg/mL, preferably 50 mg/mL.
- stirring is continued for 4-24 hours at room temperature.
- the X-ray powder diffraction pattern of the hydrobromide salt crystal form C of the compound of formula I of the present invention has characteristic peaks at 2theta values of 6.3° ⁇ 0.2°, 12.6° ⁇ 0.2°, and 18.9° ⁇ 0.2°.
- the X-ray powder diffraction pattern of the hydrobromide salt crystal form C of the compound of formula I of the present invention has a 2theta value of 6.3° ⁇ 0.2°, 8.5° ⁇ 0.2°, 12.6° ⁇ 0.2°, 18.9° There are characteristic peaks at ⁇ 0.2°, 21.3° ⁇ 0.2°, 24.4° ⁇ 0.2°, 25.2° ⁇ 0.2°.
- the present invention provides a method for preparing the hydrobromide salt crystal form C of the compound of formula I, which is specifically as follows:
- the compound of formula I is dissolved in a solvent under ultrasonic heating.
- the solvent is one or more of ethanol, acetone, acetonitrile and isopropanol.
- the concentration of the ethanol solution of hydrobromic acid is 30-60 mg/mL, preferably 50 mg/mL.
- stirring is continued for 4-24 hours at room temperature.
- the X-ray powder diffraction pattern of the phosphate crystal form D of the compound of formula I of the present invention has characteristic peaks at 2theta values of 6.1° ⁇ 0.2°, 10.9° ⁇ 0.2°, and 12.2° ⁇ 0.2°.
- the X-ray powder diffraction pattern of the phosphate crystal form D of the compound of formula I of the present invention has a 2theta value of 6.1° ⁇ 0.2°, 10.9° ⁇ 0.2°, 11.7° ⁇ 0.2°, 12.2° ⁇ 0.2 ° has a characteristic peak.
- the present invention provides a method for preparing the phosphate crystal form D of the compound of formula I, which is specifically as follows:
- the compound of formula I is dissolved in the first solvent under ultrasonic heating.
- the first solvent is one or more of ethanol, acetone, acetonitrile and isopropanol
- the second solvent is a mixed solvent of acetone and water, wherein the volume ratio of acetone to water is (mL/mL) is 7:1-9:1.
- the concentration of the ethanol solution of phosphoric acid is 30-60 mg/mL, preferably 50 mg/mL.
- stirring is continued at room temperature for 4-24 hours; after adding the second solvent, stirring is performed overnight at room temperature.
- the present invention also provides a compound comprising formula I crystal form 1, formula I compound hydrochloride crystal form A, formula I compound sulfate salt form B, formula I compound hydrobromide salt crystal form C and/or formula I compound phosphate A pharmaceutical composition of crystal form D, and comprising the compound of formula I crystal form 1, the compound of formula I hydrochloride crystal form A, the compound of formula I sulfate salt crystal form B, the compound of formula I hydrobromide salt crystal form C and/or the formula Pharmaceutical preparation of compound I phosphate crystal form D.
- the present invention also provides the compound of formula I crystal form 1, the compound of formula I hydrochloride crystal form A, the compound of formula I sulfate salt form B, the compound of formula I hydrobromide salt crystal form C and/or the compound of formula I phosphate crystal
- type D in the preparation of a medicament for treating diseases or conditions related to Jak1/TYK2, wherein the disease or condition may be an autoimmune disease or disorder, such as rheumatoid arthritis or an inflammatory disease or disorder, And cancer or tumor proliferative diseases or disorders.
- Figure 1 is the XRPD pattern of the crystal form 1 of the compound of formula I of the present invention.
- 2A is a DSC chart of the crystal form 1 of the compound of formula I of the present invention.
- Figure 2B is another DSC chart of the crystal form 1 of the compound of formula I of the present invention.
- Figure 3 is a TGA chart of the crystal form 1 of the compound of formula I of the present invention.
- Figure 4 is a DVS pattern of the crystal form 1 of the compound of formula I of the present invention.
- Figure 5 is the XRPD pattern of the hydrochloride salt form A of the compound of formula I of the present invention.
- Figure 6 is a DSC chart of the crystalline form A of the hydrochloride salt of the compound of formula I of the present invention.
- Fig. 7 is an XRPD pattern of the sulfate salt crystal form B of the compound of formula I of the present invention.
- Fig. 8 is a DSC chart of the sulfate crystal form B of the compound of formula I of the present invention.
- Fig. 9 is a TGA chart of the sulfate crystal form B of the compound of formula I of the present invention.
- Figure 10 is a DVS spectrum of the crystalline form B of the compound of formula I of the present invention.
- Figure 11 is the XRPD pattern of the hydrobromide salt crystal form C of the compound of formula I of the present invention.
- Fig. 12 is a DSC chart of the hydrobromide salt crystal form C of the compound of formula I of the present invention.
- Figure 13 is the XRPD pattern of the phosphate crystal form D of the compound of formula I of the present invention.
- Fig. 14 is a DSC chart of the phosphate crystal form D of the compound of formula I of the present invention.
- Figure 15 is a TGA chart of the phosphate crystal form D of the compound of formula I of the present invention.
- Figure 16 is a DVS spectrum of the phosphate crystal form D of the compound of formula I of the present invention.
- Figure 17 is an XRPD overlay image of the crystalline form 1 of the compound of formula I of the present invention placed for 2 weeks under high temperature and accelerated conditions.
- Fig. 18 is an XRPD overlay image of the phosphate crystal form D of the compound of formula I of the present invention placed under high temperature and accelerated conditions for 2 weeks.
- Figure 19 is a DSC overlay of the crystalline form 1 of the compound of formula I of the present invention placed for 2 weeks under high temperature and accelerated conditions.
- Figure 20 is a DSC overlay of the phosphate crystal form D of the compound of formula I of the present invention placed under high temperature and accelerated conditions for 2 weeks.
- the equipment information and usage conditions used in the present invention are as follows:
- Post-treatment 1 Take the above-mentioned filtrate (1820g, converted to 100% yield, about 40g compound of formula II), use a rotary evaporator to concentrate it to (2-3V, 80-120mL); use ethanol (150mL ⁇ 2 ) Was replaced to (2-3V, 80-120mL); 78 g of ethanol solution of the compound of formula II was obtained, the content was 47.25%, and the content yield was 92.14%.
- Post-treatment 2 Take the above-mentioned filtrate (450 g, which contains about 10 g of the compound of formula II according to 100% yield), and concentrate it to dryness with a rotary evaporator; a total of 10.5 g of brown-red solid is obtained.
- Post-treatment 3 Take the above-mentioned filtrate (450g, equivalent to about 10g compound of formula II) into the flask; use rotation to concentrate it to about 30-40mL (3-4V); use ethanol (50mL ⁇ 2) to replace the remaining concentrated to about 30-40mL (3-4V); a black oily concentrated residue is obtained, and the concentrated residue is directly put into the next reaction.
- the compound of formula I (41g) was dissolved in methanol; silica gel (50g) was added to the solution, and then the system was concentrated to dryness for use; silica gel (200g) was added to the chromatography column and compacted with an air pump; the silica gel was mixed
- the product was vacuum-baked at 50°C for 16 hours; a total of 36 g of off-white solid was obtained, with a purity of 98.5% by HPLC.
- the compound of formula I (172.6g) and acetone (2705g, ⁇ 3500mL) were added to a 5000mL three-necked flask; heated to 50-60°C, and stirred at 50-60°C for 2 hours; cooled the system to room temperature (25-30°C) ); Stir at room temperature (25-30°C) for 24 hours; under reduced pressure distillation, the volume of the material liquid in the bottle is distilled to about 0.8-0.9L; the temperature of the material liquid is reduced to 15-25°C, and purified water is added about 4.3Kg; Stir for 2h, then lower the temperature to 5-10°C, continue to stir for 2h; filter with suction, rinse the filter cake with water; bake the filter cake with a blast fan at 50-55°C for 16h; obtain 158.8g of off-white solid, The yield was 92.0%. After testing, the white solid is the crystal form 1 of the compound of formula I, and its XRPD, DSC, TGA and DVS spectra are shown
- the compound of formula I (100mg) was dissolved in acetone (2mL) at 50-55°C, cooled to room temperature and stirred for about 16 hours, added 2mL of water, stirred at room temperature for 2 hours, cooled to 10-15°C, continued to stir for 2 hours, filtered, and collected solid. After testing, the solid is the crystal form 1 of the compound of formula I, and its XRPD pattern is consistent with FIG. 1.
- the compound of formula I (200mg) was almost dissolved in 9mL methanol/water (9:1) at room temperature, and 5mg of the crystal of the compound of formula I crystal form 1 was added. The solid precipitated out. Stir at room temperature overnight. Add water (18mL) at room temperature. Stir for 4h, lower to 5-10°C and stir for 1h, filter with suction, and vacuum dry the material (about 50°C) to obtain 180mg of white solid. After testing, the white solid is the crystal form 1 of the compound of formula I, and its XRPD pattern is consistent with that in Fig. 1.
- Form 1 of the compound of formula I can also be prepared by the following method.
- Example number Crystallization solvent Formula I compound crystal form 35 Methyl tert-butyl ether Form 1 36 water Form 1 37 acetone Form 1 38 Isopropanol Form 1
- Example 41 Using the same crystallization method as in Example 41, the crystallization solvent was replaced with methanol to prepare the crystalline form of the compound of formula I.
- the obtained crystal XRPD was consistent with Figure 1 and was the crystalline form of the compound of formula I.
- the DSC had an additional value at about 151°C. The peaks are shown in Figure 2B.
- Example 47 Using the same crystallization method as in Example 47, the crystallization solvent was replaced with tetrahydrofuran to prepare the crystal form 1 of the compound of formula I.
- the XRPD pattern of the obtained crystal form 1 of the compound of formula I is consistent with FIG. 1.
- Example 49 Using the same crystallization method as in Example 49, the crystallization solvent was replaced with dichloromethane to prepare the crystal form 1 of the compound of formula I.
- the XRPD pattern of the obtained crystal form 1 of the compound of formula I is consistent with FIG. 1.
- Example number Crystallization solvent (good solvent-anti-solvent) Formula I compound crystal form 51 Methanol-water (1:10) Form 1 52 Ethanol-water (1:10) Form 1 53 Tetrahydrofuran-methyl tert-butyl ether (1:10) Form 1 54 Ethanol-methyl tert-butyl ether (1:10) Form 1 55 Methanol-methyl tert-butyl ether (1:10) Form 1 56 Acetone-methyl tert-butyl ether (1:10) Form 1 57 Isopropyl alcohol-methyl tert-butyl ether (1:10) Form 1 58 Tetrahydrofuran-dichloromethane (1:10) Form 1
- the DSC test results show that the sulfate crystal form B of the compound of formula I ( Figure 8) and the phosphate crystal form D of the compound of formula I ( Figure 14) have a single and higher melting point, indicating that their thermal stability is relatively good.
- the hydrochloride crystal form A ( Figure 6) of the formula I compound and the hydrobromide crystal form C ( Figure 12) of the formula I compound have complex thermodynamic behaviors and low crystallinity. Therefore, only the sulfate crystal form of the formula I compound B and formula I compound phosphate crystal form D were further characterized by DVS and TGA.
- the hydrochloride crystal form A of the formula I compound and the hydrobromide crystal form C of the formula I compound have a wide melting range, and the melting point is not obvious;
- the formula I compound sulfate salt crystal form B has better wettability than the formula I compound phosphate crystal form D is strong,
- the crystal form 1 of the compound of formula I and the phosphate crystal form D of the compound of formula I have good crystallinity, single melting point and relatively low hygroscopicity.
- Basic reaction buffer 20 mM Hepes (pH 7.5), 10 mM MgCl 2 , 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na 3 VO 4 , 2 mM DTT, 1% DMSO. Add the required cofactors to each kinase reaction separately.
- test results show that the compound of formula I is also a strong TYK2 inhibitor, with an IC 50 of less than 10 nM.
Abstract
Description
材料 | 纯度/级别 | 批号 | 厂家 |
式V化合物 | ≥98.0% | KM1009-1804001 | 上海睿瓦科技有限公司 |
式IV化合物 | ≥98.0% | KM1008-1804001 | 上海睿瓦科技有限公司 |
N,N-二异丙基乙胺(DIPEA) | AR | KM261A-1801002 | 上海齐奥化工科技有限公司 |
乙醇 | / | 160321047B | 南京化学试剂股份有限公司 |
甲醇 | AR | P1176856 | GENERAL-REAGENT |
四氢呋喃 | AR级 | P1167158 | GENERAL-REAGENT |
二氯甲烷 | AR | P1216848 | GENERAL-REAGENT |
乙酸乙酯(EA) | AR | P1080359 | GENERAL-REAGENT |
丙酮 | AR | P1160778 | GENERAL-REAGENT |
纯化水 | Milli-Q | 当日新制 | Milli-Q |
甲基叔丁基醚 | AR | P1135054 | GENERAL-REAGENT |
异丙醇 | HPLC | 6553IU13 | 安徽时联特种溶剂股份有限公司 |
钯炭(Pd/C) | AR | KM416A-1603001 | 陕西瑞科新材料股份有限公司 |
(R)-乳酰胺 | AR | KM1012-1806001 | 上海中乃生物医药科技有限公司 |
Et3O-BF4 | AR | KM416A-1603001 | 陕西瑞科新材料股份有限公司 |
盐酸 | AR | GM007-1809001 | 苏州周氏化学 |
碳酸钾 | 工业级 | GM009-1804001 | 上海维唐实业有限公司 |
实施例编号 | 结晶溶剂 | 式I化合物晶型 |
35 | 甲基叔丁基醚 | 晶型1 |
36 | 水 | 晶型1 |
37 | 丙酮 | 晶型1 |
38 | 异丙醇 | 晶型1 |
39 | 二氯甲烷 | 晶型1 |
40 | 乙醇 | 晶型1 |
实施例编号 | 结晶溶剂 | 式I化合物晶型 |
42 | 甲基叔丁基醚 | 晶型1 |
43 | 水 | 晶型1 |
44 | 丙酮 | 晶型1 |
45 | 异丙醇 | 晶型1 |
实施例编号 | 结晶溶剂(良溶剂-反溶剂) | 式I化合物晶型 |
51 | 甲醇-水(1:10) | 晶型1 |
52 | 乙醇-水(1:10) | 晶型1 |
53 | 四氢呋喃-甲基叔丁基醚(1:10) | 晶型1 |
54 | 乙醇-甲基叔丁基醚(1:10) | 晶型1 |
55 | 甲醇-甲基叔丁基醚(1:10) | 晶型1 |
56 | 丙酮-甲基叔丁基醚(1:10) | 晶型1 |
57 | 异丙醇-甲基叔丁基醚(1:10) | 晶型1 |
58 | 四氢呋喃-二氯甲烷(1:10) | 晶型1 |
59 | 乙醇-二氯甲烷(1:10) | 晶型1 |
60 | 甲醇-二氯甲烷(1:10) | 晶型1 |
61 | 丙酮-二氯甲烷(1:10) | 晶型1 |
62 | 异丙醇-二氯甲烷(1:10) | 晶型1 |
Claims (32)
- 一种制备式I化合物的方法,所述方法的合成路线如下:所述方法包括以下步骤:步骤1:向反应容器中加入乙醇、式IV化合物、式V化合物和DIPEA,开启搅拌;加热升温至65~90℃,保温搅拌过夜;停止反应,将体系温度降至15~30℃;向体系中滴加水,继续搅拌;过滤,洗涤滤饼;将滤饼干燥,得到式III化合物;步骤2:向反应容器中加入四氢呋喃、步骤1得到的式III化合物及钯炭;将体系用氮气置换,再用氢气置换;在0.1至1.0MPa的氢气压力下及20-35℃温度下,保温搅拌16-120小时;反应结束后,将反应液过滤,洗涤滤饼;合并滤液并浓缩,得到式II化合物浓缩物;步骤3:向第一反应容器中加入四氢呋喃、(R)-乳酰胺及Et 3O-BF 4,开启搅拌,溶解待用;向第二反应容器中加入所述式II化合物浓缩物和乙醇,将所述第二反应容器中物料加热到40-85℃;将所述第一反应容器中物料滴加到所述第二反应容器中,滴加结束,将所述第二反应容器中的混合物料在40-85℃下保温反应0.5-6小时;反应结束后,将体系的pH值调至1-3,用有机溶剂萃取,有机相弃去,用无机碱水溶液调水相pH至9-10,过滤,将滤饼干燥,得到式I化合物。
- 根据权利要求1所述的方法,在上述步骤1中:乙醇与所述式IV化合物的体积质量比为5:1至20:1,优选10:1;所述式IV化合物、所述式V化合物和DIPEA的摩尔比为1:1~1.1:2~3,优选1:1.01:2.2;开启搅拌后,氮气保护下,加热升温至65~90℃,优选70~90℃,更优选70~80℃,保温搅拌5-16小时,优选10-16小时;停止反应后将体系温度降至15~25℃;向体系中滴加的水与所述式IV化合物的体积质量比为10:1至20:1,优选15:1;向体系滴加水后在0-30℃下,优选在5-15℃下,更优选在5-10℃下,搅拌2-6小时,优选搅拌4小时;洗涤滤饼是用乙醇水溶液淋洗,乙醇水溶液中乙醇与水的体积比为1:1至1:2,优选1:1.5至1:2;乙醇水溶液与式IV化合物的体积质量比为2:1至10:1,优选2:1至5:1,更优选2:1至3:1;滤饼在45-55℃,优选50℃下真空干燥或鼓风干燥。
- 根据权利要求1或2所述的方法,在上述步骤2中:四氢呋喃与所述式III化合物的体积质量比为10:1至70:1,优选20:1至70:1;钯炭为5%Pd/C,50%湿钯炭,钯炭与所述式III化合物的质量比为0.15:1至0.16:1,优选0.15:1;在0.5-1.0MPa的氢气压力下在25-35℃下,保温搅拌24-96小时;洗涤滤饼是用四氢呋喃洗涤,合并滤液并浓缩得到的式II化合物浓缩物为式II化合物的四氢呋喃溶液,其中洗涤所用的四氢呋喃与所述式II化合物的体积质量比为2:1至4:1,优选2:1至3:1;优选地,将所述式II化合物的四氢呋喃溶液用乙醇置换得到式II化合物的乙醇溶液,其中乙醇与式II化合物的体积质量比为2:1至5:1,优选2:1至4:1,更优选2:1至3:1。
- 根据权利要求1-3中任一项所述的方法,在上述步骤3中:四氢呋喃与所述式II化合物浓缩物的体积质量比为6:1至12:1;所述式II化合物浓缩物、(R)-乳酰胺和Et 3O-BF 4的摩尔比为1:4-5:4-5;乙醇与所述式II化合物浓缩物的体积质量比为10:1至16:1,优选14:1;向所述第二反应容器中加入所述式II化合物浓缩物和乙醇之后,氮气保护下,将所述第二反应容器中物料加热到40-85℃,优选45-70℃,更优选45-50℃;将所述第二反应容器中的混合物料在45-70℃,优选45-50℃下保温反应2-5小时,优选3小时;反应结束后,用盐酸将体系的pH值调至1-3,盐酸为1M HCl或12M HCl,优选12M HCl;无机碱水溶液为饱和碳酸钠水溶液或饱和碳酸钾水溶液,优选饱和碳酸钾水溶液;反应结束后,萃取所用的有机溶剂为二氯甲烷或乙酸乙酯;将滤饼在50~55℃下真空干燥或鼓风干燥。
- 根据权利要求求1-4中任一项所述的方法,对上述步骤3得到的式I化合物进行柱层析分离纯化,其中洗脱剂为乙酸乙酯和乙醇的混合溶液。
- 根据权利要求6所述的式I化合物晶型1,其X射线粉末衍射图谱在2theta值为8.5°±0.2°、14.8°±0.2°、16.1°±0.2°、17.1°±0.2°、18.8°±0.2°、19.6°±0.2°处具有特征峰。
- 根据权利要求6或7所述的式I化合物晶型1,其X射线粉末衍射图谱在2theta值为8.5°±0.2°、14.8°±0.2°、16.1°±0.2°、17.1°±0.2°、18.8°±0.2°、19.6°±0.2°、23.8°±0.2°、25.3°±0.2°、26.1°±0.2°处具有特征峰。
- 一种如权利要求6-8中任一项所述的式I化合物晶型1的制备方法,包括:方法一:将式I化合物溶解于溶剂中,室温搅拌,向上述式I化合物的溶液中加入水,搅拌,过滤,干燥,得到式I化合物晶型1;或者方法二:向式I化合物中加入溶剂,超声得到式I化合物的混悬液,将所述式I化合物的混悬液避光并搅拌,离心,收集固体,得到式I化合物晶型1;或者方法三:向式I化合物中加入溶剂,在50-60℃下搅拌溶解,得到式I化合物的溶液,趁热将所述式I化合物的溶液过滤,滤液在-20-10℃下冷却析晶,离心,收集固体,得到式I化合物晶型1;或者方法四:向式I化合物中加入第一溶剂,超声得到式I化合物的过饱和溶液,过滤,向滤液中加入第二溶剂并搅拌,离心,收集固体,得到式I化合物晶型1。
- 根据权利要求9所述的方法,其中,在方法一中,所述溶剂选自丙酮、甲醇、水中的一种或多种;所述溶剂优选为丙酮,或者甲醇与水的混合溶剂,或丙酮与水的混合溶剂,其中甲醇与水的混合溶剂中甲醇与水的体积比为30:1至1:1,优选9:1,丙酮与水的混合溶剂中丙酮与水的体积比为6:1至1:1,优选4:1;所述溶剂与式I化合物的体积质量比为20:1至45:1,向上述式I化合物的溶液中加入的水与式I化合物的体积质量比为20:1至90:1;将式I化合物在50-60℃下溶解于溶剂中;在将式I化合物溶解于溶剂中之后,室温搅拌0.5-24小时;在向所述式I化合物的溶液中加入水之后,室温搅拌0.5-24小时,再降温至5-15℃搅拌1-4小时;在方法二中,所述溶剂选自四氢呋喃、甲基叔丁基醚、水、丙酮、异丙醇、二氯甲烷、乙醇中的一种或多种;所述式I化合物的混悬液在室温下搅拌,或者在45-55℃,优选50℃下搅拌;将所述式I化合物的混悬液避光并搅拌6-10天;在方法三中,所述溶剂选自丙酮、四氢呋喃、二氯甲烷中的一种或多种;在趁热将所述式I化合物的溶液过滤之后,以6℃/h的速率缓慢降温至室温,再在-20-10℃,优选2-8℃下冷却析晶;在方法四中,所述第一溶剂选自甲醇、乙醇、四氢呋喃、丙酮、异丙醇中的一种或多种,所述第二溶剂选自水、甲基叔丁基醚、二氯甲烷中的一种或多种;所述第一溶剂与第二溶剂的体积比为1:5至1:20,优选1:10。
- 根据权利要求11所述的式I化合物盐酸盐晶型A,其X射线粉末衍射图谱在2theta值为6.4°±0.2°、8.5°±0.2°、11.6°±0.2°、12.8°±0.2°、14.2°±0.2°、17.1°±0.2°、19.0°±0.2°处具有特征峰。
- 根据权利要求11或12所述的式I化合物盐酸盐晶型A,其X射线粉末衍射图谱在2theta值为6.4°±0.2°、8.5°±0.2°、11.6°±0.2°、12.8°±0.2°、14.2°±0.2°、17.1°±0.2°、19.0°±0.2°、19.7°±0.2°、21.3°±0.2°、24.5°±0.2°处具有特征峰。
- 一种如权利要求11-13中任一项所述的式I化合物盐酸盐晶型A的制备方法,包括:将式I化合物溶解于溶剂中,得到式I化合物的溶液,在搅拌下向所述式I化合物的溶液中加入盐酸的乙醇溶液,继续搅拌,离心,收集固体,干燥,得到式I化合物盐酸盐晶型A。
- 根据权利要求14所述的方法,其中,将式I化合物超声加热溶解于溶剂中;所述溶剂为乙醇、丙酮、乙腈和异丙醇中的一种或多种;所述盐酸的乙醇溶液的浓度为30-60mg/mL,优选50mg/mL;在加入盐酸的乙醇溶液之后,在室温下继续搅拌4-24小时。
- 根据权利要求16所述的式I化合物硫酸盐晶型B,其X射线粉末衍射图谱在2theta值为12.2°±0.2°、17.1°±0.2°、18.4°±0.2°、19.6°±0.2°、20.1°±0.2°、20.6°±0.2°、22.1°±0.2°处具有特征峰。
- 根据权利要求16或17所述的式I化合物硫酸盐晶型B,其X射线粉末衍射图谱在2theta值为12.2°±0.2°、17.1°±0.2°、18.4°±0.2°、19.6°±0.2°、20.1°±0.2°、20.6°±0.2°、22.1°±0.2°、23.5°±0.2°、26.8°±0.2°、29.3°±0.2°处具有特征峰。
- 一种如权利要求16-18中任一项所述的式I化合物硫酸盐晶型B的制备方法,包括:将式I化合物溶解于溶剂中,得到式I化合物的溶液,在搅拌下向所述式I化合物的溶液中加入硫酸的乙醇溶液,继续搅拌,离心,收集固体,干燥,得到式I化合物硫酸盐晶型B。
- 根据权利要求19所述的方法,其中,将式I化合物超声加热溶解于溶剂中;所述溶剂为乙醇、丙酮、乙腈和异丙醇中的一种或多种;所述硫酸的乙醇溶液的浓度为30-60mg/mL,优选50mg/mL;在加入硫酸的乙醇溶液之后,在室温下继续搅拌4-24小时。
- 根据权利要求21所述的式I化合物氢溴酸盐晶型C,其X射线粉末衍射图谱在2theta值为6.3°±0.2°、8.5°±0.2°、12.6°±0.2°、18.9°±0.2°、21.3°±0.2°、24.4°±0.2°、25.2°±0.2°处具有特征峰。
- 一种如权利要求21或22所述的式I化合物氢溴酸盐晶型C的制备方法,包括:将式I化合物溶解于溶剂中,得到式I化合物的溶液,在搅拌下向所述式I化合物的溶液中加入氢溴酸的乙醇溶液,继续搅拌,离心,收集固体,干燥,得到式I化合物氢溴酸盐晶型C。
- 根据权利要求23所述的方法,其中,将式I化合物超声加热溶解于溶剂中;所述溶剂为乙醇、丙酮、乙腈和异丙醇中的一种或多种;所述氢溴酸的乙醇溶液的浓度为30-60mg/mL,优选50mg/mL;在加入氢溴酸的乙醇溶液之后,在室温下继续搅拌4-24小时。
- 根据权利要求25所述的式I化合物磷酸盐晶型D,其X射线粉末衍射图谱在2theta值为6.1°±0.2°、10.9°±0.2°、11.7°±0.2°、12.2°±0.2°处具有特征峰。
- 一种如权利要求25或26所述的式I化合物磷酸盐晶型D的制备方法,包括:将式I化合物溶解于第一溶剂中,得到式I化合物的溶液,在搅拌下向所述式I化合物的溶液中加入磷酸的乙醇溶液,继续搅拌,离心,收集固体,向收集的固体中加入第二溶剂,搅拌,离心,收集固体,干燥,得到式I化合物磷酸盐晶型D。
- 根据权利要求27所述的方法,其中,将式I化合物超声加热溶解于第一溶剂中;所述第一溶剂为乙醇、丙酮、乙腈和异丙醇中的一种或多种;所述第二溶剂为丙酮与水的混合溶剂,其中丙酮与水的体积比为7:1-9:1;所述磷酸的乙醇溶液的浓度为30-60mg/mL,优选50mg/mL;在加入磷酸的乙醇溶液之后,在室温下继续搅拌4-24小时;在加入所述第二溶剂之后,在室温下搅拌过夜。
- 一种包含权利要求6-8中任一项所述的式I化合物晶型1、权利要求11-13中任一项所述的式I化合物盐酸盐晶型A、权利要求16-18中任一项所述的式I化合物硫酸盐晶型B、权利要求21或22所述的式I化合物氢溴酸盐晶型C和/或权利要求25或26所述的式I化合物磷酸盐晶型D的药物组合物。
- 一种包含权利要求6-8中任一项所述的式I化合物晶型1、权利要求11-13中任一项所述的式I化合物盐酸盐晶型A、权利要求16-18中任一项所述的式I化合物硫酸盐晶型B、权利要求21或22所述的式I化合物氢溴酸盐晶型C和/或权利要求25或26所述的式I化合物磷酸盐晶型D的药物制剂。
- 权利要求6-8中任一项所述的式I化合物晶型1、权利要求11-13中任一项所述的式I化合物盐酸盐晶型A、权利要求16-18中任一项所述的式I化合物硫酸盐晶型B、权利要求21或22所述的式I化合物氢溴酸盐晶型C和/或权利要求25或26所述的式I化合物磷酸盐晶型D在制备用于治疗与Jak1/TYK2相关的疾病或病状的药物中的用途。
- 根据权利要求31所述的用途,其中所述疾病或病状是自身免疫性疾病或障碍,例如类风湿性关节炎或炎症性疾病或障碍,以及癌症或肿瘤增殖性疾病或障碍。
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311283291.5A CN117327083A (zh) | 2019-06-06 | 2020-04-30 | 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型 |
KR1020227000069A KR20220016955A (ko) | 2019-06-06 | 2020-04-30 | 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태 |
MX2021014319A MX2021014319A (es) | 2019-06-06 | 2020-04-30 | Metodo de sintesis del compuesto de furoimidazopiridina, forma de cristal del compuesto de furoimidazopiridina, y forma de cristal de la sal del mismo. |
JP2021572485A JP7320628B2 (ja) | 2019-06-06 | 2020-04-30 | フロイミダゾピリジン化合物の合成方法、フロイミダゾピリジン化合物の結晶形態およびそれらの塩の結晶形態 |
BR112021024533A BR112021024533A2 (pt) | 2019-06-06 | 2020-04-30 | Método de síntese de composto de furoimidazopiridina, forma cristalina de composto de furoimidazopiridina, e forma cristalina de sal do mesmo |
EP23182042.4A EP4248966A3 (en) | 2019-06-06 | 2020-04-30 | Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof |
AU2020289149A AU2020289149B2 (en) | 2019-06-06 | 2020-04-30 | Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof |
EP20818305.3A EP3981771A4 (en) | 2019-06-06 | 2020-04-30 | METHOD OF SYNTHESIS OF FUROIMIDAZOPYRIDINE COMPOUND, CRYSTAL FORM OF FUROIMIDAZOPYRIDINE COMPOUND AND CRYSTAL FORM OF SALT THEREOF |
US17/615,313 US20220227777A1 (en) | 2019-06-06 | 2020-04-30 | Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof |
CA3142625A CA3142625A1 (en) | 2019-06-06 | 2020-04-30 | Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof |
CN202080036439.3A CN113906035B (zh) | 2019-06-06 | 2020-04-30 | 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型 |
EP23182049.9A EP4248967A3 (en) | 2019-06-06 | 2020-04-30 | Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof |
IL288348A IL288348A (en) | 2019-06-06 | 2021-11-24 | A method for the synthesis of a furoimidazopyridine compound, a crystalline form of a furoimidazopyridine compound, and a crystalline form of its salt |
JP2023066167A JP2023089169A (ja) | 2019-06-06 | 2023-04-14 | フロイミダゾピリジン化合物の合成方法、フロイミダゾピリジン化合物の結晶形態およびそれらの塩の結晶形態 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910490418 | 2019-06-06 | ||
CN201910490418.8 | 2019-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020244348A1 true WO2020244348A1 (zh) | 2020-12-10 |
Family
ID=73652738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/088121 WO2020244348A1 (zh) | 2019-06-06 | 2020-04-30 | 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220227777A1 (zh) |
EP (3) | EP4248967A3 (zh) |
JP (2) | JP7320628B2 (zh) |
KR (1) | KR20220016955A (zh) |
CN (2) | CN117327083A (zh) |
AU (1) | AU2020289149B2 (zh) |
BR (1) | BR112021024533A2 (zh) |
CA (1) | CA3142625A1 (zh) |
IL (1) | IL288348A (zh) |
MX (1) | MX2021014319A (zh) |
WO (1) | WO2020244348A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023035913A1 (en) * | 2021-09-13 | 2023-03-16 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Methods of treating cns disorders |
WO2023125102A1 (zh) * | 2021-12-30 | 2023-07-06 | 杭州高光制药有限公司 | 1H-呋喃并[3,2-b]咪唑并[4,5-d]吡啶化合物的合成方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104918945A (zh) * | 2012-11-01 | 2015-09-16 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
WO2018067422A1 (en) | 2016-10-03 | 2018-04-12 | Congxin Liang | Novel jak1 selective inhibitors and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA39987A (fr) * | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
WO2018112379A1 (en) * | 2016-12-16 | 2018-06-21 | Janssen Pharmaceutica Nv | Small molecule inhibitors of the jak family of kinases |
-
2020
- 2020-04-30 MX MX2021014319A patent/MX2021014319A/es unknown
- 2020-04-30 CA CA3142625A patent/CA3142625A1/en active Pending
- 2020-04-30 WO PCT/CN2020/088121 patent/WO2020244348A1/zh active Application Filing
- 2020-04-30 EP EP23182049.9A patent/EP4248967A3/en active Pending
- 2020-04-30 EP EP23182042.4A patent/EP4248966A3/en active Pending
- 2020-04-30 BR BR112021024533A patent/BR112021024533A2/pt unknown
- 2020-04-30 KR KR1020227000069A patent/KR20220016955A/ko not_active Application Discontinuation
- 2020-04-30 CN CN202311283291.5A patent/CN117327083A/zh active Pending
- 2020-04-30 EP EP20818305.3A patent/EP3981771A4/en active Pending
- 2020-04-30 CN CN202080036439.3A patent/CN113906035B/zh active Active
- 2020-04-30 AU AU2020289149A patent/AU2020289149B2/en active Active
- 2020-04-30 US US17/615,313 patent/US20220227777A1/en active Pending
- 2020-04-30 JP JP2021572485A patent/JP7320628B2/ja active Active
-
2021
- 2021-11-24 IL IL288348A patent/IL288348A/en unknown
-
2023
- 2023-04-14 JP JP2023066167A patent/JP2023089169A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104918945A (zh) * | 2012-11-01 | 2015-09-16 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
WO2018067422A1 (en) | 2016-10-03 | 2018-04-12 | Congxin Liang | Novel jak1 selective inhibitors and uses thereof |
CN108366994A (zh) * | 2016-10-03 | 2018-08-03 | 梁从新 | 新型Jak1选择性抑制剂及其用途 |
Non-Patent Citations (7)
Title |
---|
ANASTASSIADIS ET AL., NAT BIOTECHNOL., vol. 29, no. 11, 2011, pages 1039 - 45 |
GHORESCHI ET AL., IMMUNOL REV, vol. 228, no. 1, 2009, pages 273 - 287 |
GHORESCHI ET AL., IMMUNOL. REV., vol. 228, no. l, 2009, pages 273 - 287 |
GUSCHIN ET AL., EMBO J., vol. 14, no. 7, 1995, pages 1421 - 1429 |
MAINI ET AL., ARTHRITIS RHEUM, vol. 54, no. 9, 2006, pages 2817 - 2829 |
MURRAY, J. IMMUNOL., vol. 178, no. 5, 2007, pages 2623 - 2629 |
SCHINDLER ET AL., J. BIOL. CHEM., vol. 282, no. 28, 2007, pages 20059 - 20063 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023035913A1 (en) * | 2021-09-13 | 2023-03-16 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Methods of treating cns disorders |
WO2023125102A1 (zh) * | 2021-12-30 | 2023-07-06 | 杭州高光制药有限公司 | 1H-呋喃并[3,2-b]咪唑并[4,5-d]吡啶化合物的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3981771A1 (en) | 2022-04-13 |
CN113906035B (zh) | 2023-11-10 |
CN113906035A (zh) | 2022-01-07 |
CA3142625A1 (en) | 2020-12-10 |
EP3981771A4 (en) | 2023-03-15 |
BR112021024533A2 (pt) | 2022-01-18 |
KR20220016955A (ko) | 2022-02-10 |
US20220227777A1 (en) | 2022-07-21 |
IL288348A (en) | 2022-01-01 |
JP2022543183A (ja) | 2022-10-11 |
EP4248967A3 (en) | 2023-10-11 |
JP2023089169A (ja) | 2023-06-27 |
AU2020289149A1 (en) | 2022-01-06 |
CN117327083A (zh) | 2024-01-02 |
JP7320628B2 (ja) | 2023-08-03 |
MX2021014319A (es) | 2022-01-26 |
AU2020289149B2 (en) | 2023-05-11 |
EP4248967A2 (en) | 2023-09-27 |
EP4248966A2 (en) | 2023-09-27 |
EP4248966A3 (en) | 2023-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017193914A1 (zh) | 克立硼罗游离形式的晶型及其制备方法和用途 | |
WO2020244348A1 (zh) | 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型 | |
WO2017152707A1 (zh) | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 | |
CN107531678A (zh) | Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用 | |
CN113840604A (zh) | Jak2抑制剂的结晶形式 | |
KR20170032330A (ko) | C-Met 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도 | |
WO2018157803A1 (zh) | 维奈妥拉的晶型及其制备方法 | |
WO2020244349A1 (zh) | 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物 | |
WO2018006870A1 (zh) | Galunisertib的晶型及其制备方法和用途 | |
WO2019228171A1 (zh) | 一种稠环嘧啶类化合物的盐、晶型及其制备方法和应用 | |
US20220332706A1 (en) | Crystalline forms of a jak2 inhibitor | |
US9688687B2 (en) | Polymorphic forms of icotinib phosphate and uses thereof | |
WO2020083188A1 (zh) | 一种酪氨酸激酶抑制剂的一马来酸盐的晶型及其制备方法 | |
WO2018137670A1 (zh) | 一种病毒蛋白抑制剂药物vx-787的晶型及其制备方法和用途 | |
EA045390B1 (ru) | Способ синтеза фуроимидазопиридинового соединения, кристаллическая форма фуроимидазопиридинового соединения и кристаллическая форма его соли | |
EP4230625A1 (en) | Crystal form of multi-substituted benzene ring compound maleate, and preparation method therefor and use thereof | |
WO2023011428A1 (zh) | Ripk1抑制剂的晶型及其酸式盐和其酸式盐的晶型 | |
WO2022247772A1 (zh) | 一种含氧杂环化合物的晶型、其制备方法及应用 | |
EP4349835A1 (en) | Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof | |
WO2019105217A1 (zh) | Galunisertib的晶型及其制备方法和用途 | |
WO2019011336A1 (zh) | Qaw-039的晶型及其制备方法和用途 | |
WO2019148789A1 (zh) | 布格替尼的晶型及其制备方法 | |
WO2019091400A1 (zh) | 吡啶并嘧啶类化合物的盐型和晶型及其制备方法 | |
WO2019042383A1 (zh) | Galunisertib的晶型及其制备方法和用途 | |
CN115427413A (zh) | 磺酰胺类化合物的晶型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20818305 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3142625 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021572485 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021024533 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20227000069 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020289149 Country of ref document: AU Date of ref document: 20200430 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2020818305 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112021024533 Country of ref document: BR Kind code of ref document: A2 Effective date: 20211203 |